Toggle Main Menu Toggle Search

ePrints

Development and validation of a LC-MS/MS method for the quantification of the checkpoint kinase 1 inhibitor SRA737 in human plasma

Lookup NU author(s): Monique Zangarini, Philip Berry, Julieann Sludden, Professor Gareth Veal

Downloads


Licence

This is the authors' accepted manuscript of an article that has been published in its final definitive form by Future Medicine Ltd., 2017.

For re-use rights please refer to the publisher's terms and conditions.


Abstract

© 2017 Future Science Ltd. Aim: SRA737 is an orally active small-molecule inhibitor of checkpoint kinase 1 being investigated in an oncology setting. A HPLC-MS/MS method for quantifying plasma concentrations of SRA737 was validated. Methods & results: Sample preparation involved protein precipitation with acetonitrile following addition of 13C15N-deuterated SRA737 as internal standard. A rapid and selective method was fully validated across a range of 5-20,000 ng/ml, exhibiting good sensitivity, overall precision (expressed as coefficient of variation) ≤8.0% and accuracy 96-102%. Consistently high recovery was observed, with no matrix effect and a lower limit of quantitation of 5 ng/ml. Conclusion: A novel method for analyzing SRA737 in human plasma has been validated and is now being utilized for quantification of SRA737 in a Phase I trial.


Publication metadata

Author(s): Zangarini M, Berry P, Sludden J, Raynaud FI, Banerji U, Jones P, Edwards D, Veal GJ

Publication type: Article

Publication status: Published

Journal: Bioanalysis

Year: 2017

Volume: 9

Issue: 13

Pages: 1001-1010

Print publication date: 01/07/2017

Online publication date: 10/07/2017

Acceptance date: 02/04/2016

ISSN (print): 1757-6180

ISSN (electronic): 1757-6199

Publisher: Future Medicine Ltd.

URL: https://doi.org/10.4155/bio-2017-0043

DOI: 10.4155/bio-2017-0043


Altmetrics

Altmetrics provided by Altmetric


Actions

    Link to this publication


Share